Get the Stockscreener App
1.24
70.69%
-2.99
After Hours:
1.25
0.01
+0.81%
Aldeyra Therapeutics Inc stock is traded at $1.24, with a volume of 51.79M.
It is down -70.69% in the last 24 hours and down -75.92% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$4.23
Open:
$1.12
24h Volume:
51.79M
Relative Volume:
26.85
Market Cap:
$74.63M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.1994
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-75.25%
1M Performance:
-75.92%
6M Performance:
-74.69%
1Y Performance:
-80.35%
1-Day Range:
$1.07
$1.51
1-Week Range:
$1.07
$5.10
52-Week Range:
$1.07
$6.87
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.24 | 254.57M | 0 | -33.85M | -33.35M | -0.5638 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.49 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.05 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.03 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.42 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.33 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Aldeyra Therapeutics stock plunges 70% after third FDA rejection - The Business Journals
Aldeyra Therapeutics stock maintained at Buy by BTIG after FDA setback - Investing.com
Third Time Is Not The Charm For Aldeyra - Citeline News & Insights
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton ... - Bluefield Daily Telegraph
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For - GlobeNewswire
$ALDX ALERT: Aldeyra Therapeutics, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm - GlobeNewswire Inc.
Aldeyra plunges as FDA rejects dry eye disease therapy - MSN
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lacking Evidence, FDA Rejects Aldeyra Dry Eye Disease Drug - MedCity News
Aldeyra receives FDA rejection for dry eye treatment reproxalap - MSN
Why Aldeyra Therapeutics Stock Just Hit 52-Week LowAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Aldeyra Therapeutics Sees Unusually High Options Volume (NASDAQ:ALDX) - MarketBeat
Aldeyra collects third CRL for reproxalap in dry eye disease - BioWorld MedTech
FDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings - Fierce Biotech
Aldeyra Therapeutics Shares Plummet Amid Financial Concerns - StocksToTrade
Aldeyra Therapeutics Receives FDA Complete Response Letter for Reproxalap Dry Eye Disease Treatment, No Additional Trials Required 1 - Minichart
Aldeyra Therapeutics Shareholders Are Encouraged to Reach - GlobeNewswire
Third FDA Rejection for Aldeyra’s Dry Eye Disease Drug Sends Shares Plummeting - BioSpace
Aldeyra Therapeutics (ALDX) Faces FDA Rejection for Dry Eye Drug - GuruFocus
Nasdaq Surges Over 100 Points; Academy Sports And Outdoors Posts Downbeat Earnings - Benzinga
Aldeyra Therapeutics Sees Stock Movement Amid Latest Developments - timothysykes.com
US FDA declines to approve Aldeyra’s drug for eye disorder - KFGO
US FDA declines to approve Aldeyra’s eye disorder drug, shares slump - PharmaLive
Aldeyra receives third complete response letter for reproxalap - Ophthalmology Times
FDA rejects Aldeyra’s dry eye disease drug application - Investing.com
Aldeyra (ALDX) Faces FDA Setback on Dry Eye Disease Drug Applica - GuruFocus
Aldeyra Therapeutics (ALDX) Faces Major Setback as FDA Rejects E - GuruFocus
US FDA declines to approve Aldeyra's eye disorder drug, shares slump - marketscreener.com
Aldeyra Therapeutics Shares Fall as Drug Rejected by Regulator on Efficacy Concerns - marketscreener.com
Why Did ALDX Stock Tank 75% In Pre-Market Today? - Asianet Newsable
FDA Issues Second Complete Response Letter for Reproxalap - The American Journal of Managed Care® (AJMC®)
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today? - TipRanks
Aldeyra Therapeutics shares down 73% premarket after US FDA declines to approve eye disorder drug - marketscreener.com
Aldeyra plunges on FDA rejection of lead drug (ALDX:NASDAQ) - Seeking Alpha
The U.S. Food and Drug Administration (FDA) recently provided key recommendations to Aldeyra Therapeutics Inc, requesting the company to conduct an in-depth analysis of the failures encountered in clinical trials of its ophthalmic drug Reproxalap. - Bitget
Aldeyra Therapeutics receives FDA complete response letter for reproxalap; $70M runway into 2028 - TradingView
FDA rejects Aldeyra (NASDAQ: ALDX) reproxalap NDA for dry eye - Stock Titan
Dry eye drug’s fast-acting promise stalls as FDA questions trial results - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
FDA declines to approve Aldeyra's dry-eye disease drug for third time - FirstWord Pharma
Aldeyra Therapeutics faces FDA PDUFA date extension - MSN
Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Awaits FDA Verdict On Dry Eye Drug Reproxalap - RTTNews
ALDX stock garners retail interest: Investors debate dry eye treatment approval amid long wait - MSN
Is Aldeyra Therapeutics waving red flags with consequences? - statnews.com
ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait - Stocktwits
Aldeyra Therapeutics: Investor Attention Shifts to Upcoming Catalysts - AD HOC NEWS
Movement Recap: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Aldeyra Therapeutics Inc (ALDX) Stock Price & 30 Year Financial Data - GuruFocus
HC Wainwright Analysts Boost Earnings Estimates for ALDX - MarketBeat
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving Average – Here’s What Happened - Defense World
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):